

© 2010 General Electric Company - All rights reserved.  
GE, GE Monogram, Lunar and enCORE are trademarks  
of General Electric Company.

FRAX is a registered trademark of the World Health  
Organization Collaborating Centre for Metabolic Bone  
Diseases, University of Sheffield, UK .

General Electric Company reserves the right to make  
changes in specifications and features shown herein, or  
discontinue the product described at any time without  
notice or obligation. Contact your GE representative for  
the most current information.

GE Medical Systems, Ultrasound & Primary Care  
Diagnostics, LLC, a General Electric company, doing  
business as GE Healthcare.

**Lunar Product Division Americas**  
**GE Healthcare Lunar**  
Global Headquarters  
PO Box 7550  
Madison, WI 53707-7550  
T: +1-888-795-8627 (option 9, then option 9)  
F: +1-608-223-2482

**Lunar Product Division**  
**Europe, Middle-East & Africa**  
**GE Healthcare Lunar**  
Kouterveldstraat 20  
B-1831 Diegem, Belgium  
T: +32-2-7197217  
F: +32-2-7197359  
info.lunar@ge.com

**Lunar Densitometry**  
**Asia & Pacific Headquarters**  
**GE Healthcare Lunar**  
3/F GE China Technology Park  
No. 1 Hua Tuo Road  
Shanghai 201203, China  
T: +86-21-38777888 (Ext. 60128 or 60480)  
F: +86-21-38777451

**Indications For Use: FRAX 10-Year Fracture Risk  
Software Option for GE Lunar Bone Densitometers**  
The FRAX 10-Year Fracture Risk software option is an  
accessory to currently marketed GE Lunar bone  
densitometer devices, which are intended to estimate  
the bone mineral density and body composition (lean  
and fat tissue mass) of patients when medically  
indicated by their physicians.

This software option is intended to provide an  
assessment of 10-year fracture risk. The option provides  
an estimate of 10-year probability of hip fracture and  
10-year probability of a major osteoporotic fracture  
(clinical spine, forearm, hip or shoulder fracture). This  
estimate is based on the patient's age, sex, country,  
ethnicity, height, weight, femur neck BMD T-score, and  
the presence or absence of several risk factors and is  
computed using the FRAX Fracture Risk Assessment Tool  
endorsed by the World Health Organization (WHO). The  
tool has been validated for men and post-menopausal  
women between 40 and 90 years old. The output is  
provided in a separate screen display and report that  
can be viewed or printed or exported to an optional  
physician report generator tool.

The results can be used by a physician in conjunction  
with other clinical risk factors as an aid in the diagnosis  
of osteoporosis and medical conditions leading to  
reduced bone density, and ultimately in the assessment  
of fracture risk.

GE Healthcare

FRAX

A new clinical tool for identifying  
patients at high risk of fracture

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that  
are shaping a new age of patient care. Our broad expertise in medical imaging and  
information technologies, medical diagnostics, patient monitoring systems, drug  
discovery, biopharmaceutical manufacturing technologies, performance improvement  
and performance solutions services help our customers to deliver better care to more  
people around the world at a lower cost. In addition, we partner with healthcare  
leaders, striving to leverage the global policy change necessary to implement a  
successful shift to sustainable healthcare systems.

Our **healthymagination** vision for the future invites the world to join us on our journey  
as we continuously develop innovations focused on reducing costs, increasing access  
and improving quality and efficiency around the world. Headquartered in the United  
Kingdom, GE Healthcare is a \$17 billion unit of General Electric Company (NYSE: GE).  
Worldwide, GE Healthcare employs more than 46,000 people committed to serving  
healthcare professionals and their patients in more than 100 countries. For more  
information about GE Healthcare, visit our website at [www.gehealthcare.com](http://www.gehealthcare.com)

To receive Lunar News online, please register for SmartMail. Go  
to [www.gehealthcare.com](http://www.gehealthcare.com) and click on the SmartMail icon and  
complete the registration form. Select online newsletter, select BMD,  
click submit and you will automatically receive the newsletter.




# FRAX: Individualized fracture risk assessment

## FRAX® fracture risk tool

Provides an estimate of 10-year probability of a major fracture (clinical spine, wrist, proximal humerus and hip) or hip alone. This estimate is based on femoral neck BMD and clinical risk factors as shown in the table below.

Licensed from the World Health Organization (WHO), FRAX has been seamlessly integrated into the enCORE software (version 13.31) to make it easy to calculate and comply with new osteoporosis guidelines incorporating FRAX.



**Figure 1:** Percentage of non-vertebral, hip, upper humerus and wrist fractures that occurred in men and women with osteoporosis, osteopenia or normal BMD using gender specific T-scores.5

Risk factors included in the WHO fracture risk assessment model <sup>1</sup>
Age
Gender
Personal history of fracture
Femoral neck BMD
Low body mass index (kg/m <sup>2</sup> )
Glucocorticoid therapy
Secondary osteoporosis (e.g., rheumatoid arthritis)
Parental history of hip fracture
Current smoking
Alcohol intake 3 or more drinks/day

## Identify those most at risk

The FRAX model is useful in identifying the subset of patients in the low bone mass category most likely to benefit from treatment (those with a T-score of –1 to –2.5, categorized as having osteopenia). This is an important advance, since the majority of fractures do not occur in patients with osteoporosis.<sup>1</sup> (See Figure 1)

The FRAX model also includes men and different ethnicities, two groups within which osteoporotic fractures are increasing. However, osteoporosis testing and intervention have been largely neglected.<sup>2</sup>

The FRAX model also aids in identifying persons with co-morbid conditions that increase fracture risk, and targets these high-risk subjects for intervention.<sup>3</sup>

## Enhanced fracture-risk communication: Better shared decision-making

Compared to BMD T-scores *alone*, the use of 10-year fracture probability may provide a better basis for shared decision-making between patient and physician.<sup>2</sup>

## Intervention thresholds for the USA

A recent economic analysis by the National Osteoporosis Foundation (NOF) found that osteoporosis treatment would be cost-effective for patients with a 10-year fracture probability of 3% or higher or a 10-year probability of a major osteoporosis-related fracture of 20% or higher.<sup>1,4</sup> However, it must be emphasized that a patient’s estimated fracture probability cannot be the sole basis for treatment decisions.<sup>2</sup>

### References:

1. National Osteoporosis Foundation. 2008 Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation.
2. Dawson-Hughes B, Tosteson ANA, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449-458.
3. Siris E, Delmas PD. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int 2008;19:383-384.
4. Tosteson ANA, Melton LJ III, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int 2008;19:437-447.
5. Schuit, SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 2004;34:195-202.

## Guidelines incorporating FRAX:

**The National Osteoporosis Foundation (NOF) Clinician’s Guide to prevention and treatment of osteoporosis 2008.**  
[www.nof.org/professionals/NOF\\_Clinicians\\_Guide.pdf](http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf)

**European guidance for the diagnosis and management of osteoporosis in postmenopausal women.** Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster, JY, Borgström F, Rizzoli R, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Osteoporos Int (2008) 19:399-428.


**Osteoporosis: Clinical guideline for prevention and treatment (UK)** [National Osteoporosis Guideline Group (NOGG) on behalf of the Bone Research Society, British Geriatrics Society, British Orthopaedic Association, British Society of Rheumatology, National Osteoporosis Society, Osteoporosis 2000, Osteoporosis Dorset, Primary Care Rheumatology Society, Royal College of Physicians and Society for Endocrinology]]  
[www.iofbonehealth.org/health-professionals/national-regional-guidelines/references.html#ref\\_12](http://www.iofbonehealth.org/health-professionals/national-regional-guidelines/references.html#ref_12)

## Other informational resources on FRAX:

**FRAX Identifying people at high risk of fracture.** 16-page report aimed to bring understanding of FRAX to health professionals, policy makers, and interested laypersons. Authored by Eugene McCloskey, International Osteoporosis Foundation.  
[www.iofbonehealth.org/publications/frax.html](http://www.iofbonehealth.org/publications/frax.html)

**WHO On-Line Fracture Risk Assessment Tool**  
[www.shef.ac.uk/FRAX](http://www.shef.ac.uk/FRAX)

**IOF FRAX Educational Slide-kit.**  
[www.iofbonehealth.org/health-professionals/frax.html](http://www.iofbonehealth.org/health-professionals/frax.html)



**Figure 2:** FRAX tool as implemented in the enCORE software.